ADMA Q4 revenue $50M (+90% YoY); FY 2023 guidance >$210M, first-time EBITDA in H2 2023

ADMA BIOLOGICS, INC.

Q4 2022 total revenues $50.0M (+90% YoY); gross profit $14.2M (vs $3.5M); net loss $12.2M ($0.06 loss per share).
Full year 2022 revenues $154.1M (+90% YoY); net loss $65.9M (improved from $71.6M).
FY 2023 total revenue expected to exceed $210M; first-time positive EBITDA no later than second half 2023.
2024-2025 revenue targets: $250M+ in 2024, $300M+ thereafter; gross margins 40-50%, net income margins 20-30%.
ASCENIV production to expand to 4,400L scale; BioCenters on track for 10 FDA-licensed sites by year-end 2023; strategic review continues with Morgan Stanley.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ADMA BIOLOGICS, INC. reported the three months ended December 31, 2022 results: revenue $50.0 million.

Period: the three months ended December 31, 2022
Revenue: $50.0 million
Result: reported results

Exact text from the filing

Total revenues for the quarter ended December 31, 2022 were $50.0 million, as compared to $26.4 million during the fourth quarter of 2021, an increase of $23.6 million, or approximately 90%.

View on SEC.gov

Browse all earnings releases →

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-23-013402

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.